Findings lay groundwork for human clinical trial planned for August 2016
A new scientific study has identified why colorectal cancer cells depend on a specific nutrient, and a way to starve them of it. Over one million men and women are living with colorectal cancer in the United States. The National Cancer Institute estimates 4.5% of all men and women will be diagnosed with the cancer during their lifetime, making it the third most common non-skin cancer.
In the study published online in Nature Communications, researchers showed how certain colorectal cancer cells reprogram their metabolism using glutamine, a non-essential amino acid. Many cancer cells rely on glutamine to survive. How they become so dependent on the molecule is hotly debated in the field.
Researchers studied a subset of colorectal cancer cells containing a genetic mutation called PIK3CA. This mutation is located in a gene critical for cell division and movement, and is found in approximately one third of all colorectal cancers. The mutation is also the most commonly identified genetic mutation across all cancers, making the results of the study universally appealing.
Researchers were interested in determining whether or not the common PIK3CA mutation contributes to changes in cancer cell metabolism, such as how nutrients like glutamine are processed. Normally, glutamine is broken down by cancer cells into several other molecules with the help of specific enzymes. This complicated system helps produce adenosine triphosphate, the energy currency of all cells, and other molecules critical for colorectal cancer cell growth.
The researchers found that colorectal cells with the PIK3CA mutation broke down significantly more glutamine than cells without the mutation. The researchers identified several enzymes involved in the process that are more active in the mutant cancer cells than in other cell types, explaining the increased need for glutamine. These enzymes become overactive in the mutant cancer cells due to a cascade of signals led by the protein encoded by mutant PIK3CA gene. This finding represents a novel and important link between the common PIK3CA mutation and altered glutamine metabolism in cancer cells.
Zhenghe John Wang, PhD, professor of genetics and genome sciences and co-leader of the Cancer Genetics Program at Case Western Reserve University School of Medicine helped lead the study. “In layman’s terms, we discovered that colon cancers with PIK3CA oncogenic mutations are addicted to glutamine, a particular nutrient for cancer cells. We also demonstrated that these cancers can be starved to death by depriving glutamine with drugs.”
When the researchers lowered the amount of glutamine available to mutant cancer cells growing in laboratory dishes, the cancer cells died. This discovery led the team to investigate the effects of blocking glutamine availability in mice with colorectal cancer tumors containing the common PIK3CA mutation. Wang and colleagues found that exposing these mice to a compound that blocks glutamine metabolism consistently suppressed tumor growth. They did not observe the same effect on tumors without the mutation. Together, these results provide a promising new therapeutic avenue to suppress growth of colorectal tumors with the PIK3CA mutation. The researchers have filed a patent application based on the unique mechanism of tumor suppression they have identified and the work is available for licensing.
“This study provides the basis for a colon cancer treatment clinical trial that will be started in the summer at the University Hospitals Seidman Cancer Center,” according to Neal Meropol, MD, Dr. Lester E. Coleman, Jr. Professor of Cancer Research and Therapeutics, chief of the division of hematology and oncology, and principal investigator for the trial. The phase I/II study will test the effects of a glutamine metabolism inhibitor in patients with advanced colorectal tumors.
The Latest on: Colorectal cancers
via Google News
The Latest on: Colorectal cancers
- Cultivating Resilience Through Colon Canceron October 9, 2020 at 4:03 pm
Burgess wants to share her personal journey, and encourage others who are currently battling cancer. Danielle Ripley-Burgess is a two-time colon cancer survivor first diagnosed at age 17 and an ...
- Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Centeron October 9, 2020 at 5:00 am
COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients Marseille, France, October 9, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced the company will be ...
- The number and clonality of TCRs are associated with the prognosis of colorectal canceron October 6, 2020 at 11:14 am
Colorectal cancer (CRC) is the third most common cancer in the world, with more than one and a half million new cases diagnosed annually. Approximately 20% of diagnosed stage II patients experience ...
- THC Prevents Colon Cancer In Mice, Findings Suggeston October 6, 2020 at 9:05 am
People suffering from inflammatory bowel disease and chronic inflammation are on the fast track to colon cancer, but prevention might begin with cannabis Young adults typically brush off the risk of ...
- Colorectal cancer treatment: The winning combinationson October 6, 2020 at 8:22 am
Chemotherapy-based cancer treatment has distressing side effects for patients and increases the risk of developing resistance to the treatment. In an attempt to solve these problems, scientists from ...
- 4 things you and your family should know about colon canceron October 6, 2020 at 7:00 am
More than 150,000 Americans develop colorectal cancer each year, making it the second most common cancer-related cause of death in the United States. Here are four things you should know about colon ...
- Colon cancer rates in younger adults are risingon October 6, 2020 at 1:27 am
In 2020, there will be about 18,000 cases of colorectal cancer diagnosed in people under 50, according to the Colon Cancer Coalition.
- Cannabis compound prevents colon cancer in miceon October 3, 2020 at 12:38 am
New research in mice suggests that tetrahydrocannabinol, the active compound in cannabis, has anti-inflammatory properties and may prevent colon cancer.
- From Diagnosis to Treatment: The Compounding Effect of Colon Cancer Disparities in Americaon October 1, 2020 at 11:46 am
As part of U.S. News’ ongoing series on health equity, U.S. News data analysts took a closer look at disparities in colon cancer and found stark differences in who was diagnosed ...
- Your Health At Home: Colorectal Cancer Screening During COVID-19on September 30, 2020 at 10:46 am
As Americans adjust to the unprecedented changes they have had to make as a result of the coronavirus pandemic, it can be easy to forget about pre-pandemic priorities.
via Bing News